Mona Malik, Ph.D. is a co-author of this article discussing how agents targeting topoisomerases are active against a wide range of human tumors. Stabilization of covalent complexes, converting topoisomerases into DNA-damaging agents, is an essential aspect of cell killing by these drugs. A unique aspect of the repair of topoisomerase-mediated DNA damage is the requirement for pathways that can remove protein covalently bound to DNA. Tyrosyl-DNA phosphodiesterase (Tdp1) is an enzyme that removes phosphotyrosyl moieties bound to the 3″ end of DNA.
Mona Malik, Ph.D., supports patent prosecution and litigation and provides technical and scientific guidance in various fields of life sciences, including cell biology, immunology/immunotherapy, genetics, biochemistry, pharmacology, virology, oncology, plant sciences and agriculture. With an advance degree and more than a dozen years of research experience, Mona brings noteworthy credentials to the patent issues of intellectual property. She earned a Ph.D. from the University of Cambridge after investigating complex mechanisms of chromosomal gene recombination and gene replacement.
To read the full article, click the link below:
